Original Article

The Effect of Add-on Memantine in New Onset Combat-Related Posttraumatic Stress Disorder Core Symptoms: A Pilot Study

Abstract

Objective: Studies using standard neuropsychological instrumentation have shown memory deficits in posttraumatic stress disorder (PTSD) patients. We examined the efficacy and safety of memantine in new cases of combat-related PTSD in the military by conducting a 16-week prospective double-blind randomized controlled trial.

Method: Twenty-six new combat-related PTSD cases were recruited from among the military personnel based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Patients were assigned to memantine and Placebo groups. They were monitored at baseline, week eight, and week 16. Memantine was added to each patient's current medication with an initial dosage of 5 mg/day, raised by 5 mg/day every week until it reached the maintenance level of 20 mg/day. The concurrent drugs were essentially kept unchanged during the trial. The primary outcome was PTSD severity as assessed by the Clinician-administered PTSD Scale (CAPS). The CAPS is a valid and reliable tool for the diagnosis of PTSD and measurement of its severity according to the DSM–4.

Results: CAPS mean score in baseline (P = 0.811) and weeks eight (P = 0.389) and 16 (P = 0.066) did not show any significant differences between the two groups. The mean CAPS score in the memantine group significantly (P = 0.006) decreased (Mean differences = -8.79) compared to the placebo group, showing that intervention with memantine was effective. The mean total CAPS in weeks eight (Mean differences = -14.21) and 16 (Mean differences = -27) were less than the baseline, which was significantly meaningful (P < 0.001).

Conclusion: Findings of this study suggest that add-on memantine can be effective in veteran patients with PTSD. So our data provide useful insight into the management of new cases of combat-related PTSD.

1. Koenen KC, Ratanatharathorn A, Ng L, McLaughlin KA, Bromet EJ, Stein DJ, et al. Posttraumatic stress disorder in the World Mental Health Surveys. Psychol Med. 2017;47(13):2260-74.
2. Ehlers A, Clark DM. A cognitive model of posttraumatic stress disorder. Behav Res Ther. 2000;38(4):319-45.
3. Smith TC, Ryan MA, Wingard DL, Slymen DJ, Sallis JF, Kritz-Silverstein D. New onset and persistent symptoms of post-traumatic stress disorder self reported after deployment and combat exposures: prospective population based US military cohort study. Brit Med Jour. 2008;336(7640):366-71.
4. Zargar F, Foruzandeh E, Omidi A, Mohammadi A. Psychological health and marital adjustment in Iranian employed veterans and veterans receiving disability pension. Iran Red Crescent Med J. 2014;16(7):e10219.
5. Sepahvand H, Mokhtari Hashtjini M, Salesi M, Sahraei H, Pirzad Jahromi G. Prevalence of Post-Traumatic Stress Disorder (PTSD) in Iranian Population Following Disasters and Wars: A Systematic Review and Meta-Analysis. Iran J Psychiat Behav Sci. 2019;13(1):e66124.
6. Pitman RK, Rasmusson AM, Koenen KC, Shin LM, Orr SP, Gilbertson MW, et al. Biological studies of post-traumatic stress disorder. Nat Rev Neurosci. 2012;13(11):769-87.
7. Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci. 2011;13(1):22-37.
8. Reul JM, Nutt DJ. Glutamate and cortisol--a critical confluence in PTSD? J Psychopharmacol. 2008;22(5):469-72.
9. Abdallah CG, Averill LA, Krystal JH. Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann N Y Acad Sci. 2015;1344(1):66-77.
10. Averill LA, Purohit P, Averill CL, Boesl MA, Krystal JH, Abdallah CG. Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies. Neurosci Lett. 2017;649:147-55.
11. Gabr RW, Birkle DL, Azzaro AJ. Stimulation of the amygdala by glutamate facilitates corticotropin-releasing factor release from the median eminence and activation of the hypothalamic-pituitary-adrenal axis in stressed rats. Neuroendocrinology. 1995;62(4):333-9.
12. Zelena D, Mergl Z, Makara GB. Glutamate agonists activate the hypothalamic-pituitary-adrenal axis through hypothalamic paraventricular nucleus but not through vasopressinerg neurons. Brain Res. 2005;1031(2):185-93.
13. Tokarev D, Jezová D. Effect of central administration of the non-NMDA receptor antagonist DNQX on ACTH and corticosterone release before and during immobilization stress. Methods Find Exp Clin Pharmacol. 1997;19(5):323-8.
14. Chambers RA, Bremner JD, Moghaddam B, Southwick SM, Charney DS, Krystal JH. Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Semin Clin Neuropsychiatry. 1999;4(4):274-81.
15. Jumaili WA, Trivedi C, Chao T, Kubosumi A, Jain S. The safety and efficacy of ketamine NMDA receptor blocker as a therapeutic intervention for PTSD review of a randomized clinical trial. Behav Brain Res. 2022;424:113804.
16. Attari A, Rajabi F, Maracy MR. D-cycloserine for treatment of numbing and avoidance in chronic post traumatic stress disorder: A randomized, double blind, clinical trial. J Res Med Sci. 2014;19(7):592-8.
17. Czarnecka K, Chuchmacz J, Wójtowicz P, Szymański P. Memantine in neurological disorders - schizophrenia and depression. J Mol Med (Berl). 2021;99(3):327-34.
18. Omranifard V, Rajabi F, Mohammadian-Sichani M, Maracy M. The effect of add-on memantine on global function and quality of life in schizophrenia: A randomized, double-blind, controlled, clinical trial. Adv Biomed Res. 2015;4:211.
19. Omranifard V, Rajabi F, Mohammadian-Sichani M, Maracy MR. The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: a doubleblind, randomized, controlled trial. Actas Esp Psiquiatr. 2017;45(3):108-15.
20. Askari S, Mokhtari S, Shariat SV, Shariati B, Yarahmadi M, Shalbafan M. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial. BMC Psychiatry. 2022;22(1):34.
21. Hadi F, Kashefinejad S, Kamalzadeh L, Hoobehfekr S, Shalbafan M. Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis. BMC Pharmacol Toxicol. 2021;22(1):69.
22. Hori H, Itoh M, Matsui M, Kamo T, Saito T, Nishimatsu Y, et al. The efficacy of memantine in the treatment of civilian posttraumatic stress disorder: an open-label trial. Eur J Psychotraumatol. 2021;12(1):1859821.
23. Di Iorio G, Baroni G, Lorusso M, Montemitro C, Spano MC, di Giannantonio M. Efficacy of Memantine in Schizophrenic Patients: A Systematic Review. J Amino Acids. 2017;2017:7021071.
24. Cénat JM, Blais-Rochette C, Kokou-Kpolou CK, Noorishad PG, Mukunzi JN, McIntee SE, et al. Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: A systematic review and meta-analysis. Psychiatry Res. 2021;295:113599.
25. Shen X, Yan S, Jiang H, Cao H, Dowling R, Feng J, et al. Post-traumatic Stress Disorder and Associated Factors 1 Year After the Beginning of the COVID-19 Pandemic Among Chinese Residents. Front Psychiatry. 2021;12:766127.
26. Weathers FW, Keane TM, Davidson JR. Clinician-administered PTSD scale: a review of the first ten years of research. Depress Anxiety. 2001;13(3):132-56.
27. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, et al. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995;8(1):75-90.
28. Cicchetti D, Fontana A, Showalter D. Evaluating the reliability of multiple assessments of PTSD symptomatology: multiple examiners, one patient. Psychiatry Res. 2009;166(2-3):269-80.
29. Ramaswamy S, Madabushi J, Hunziker J, Bhatia SC, Petty F. An Open-Label Trial of Memantine for Cognitive Impairment in Patients with Posttraumatic Stress Disorder. J Aging Res. 2015;2015:934162.
30. Battista MA, Hierholzer R, Khouzam HR, Barlow A, O'Toole S. Pilot trial of memantine in the treatment of posttraumatic stress disorder. Psychiatry. 2007;70(2):167-74.
31. Gorbachenko ‎VA, ‎Lukyanetz ‎EA. Effects of memantine on the passive avoidance test in young rats. Fiziolohichnyĭ Zhurnal. 2020; 66(5):3-10.
Files
IssueVol 18 No 3 (2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijps.v18i3.13003
Keywords
Glutamate Memantin N-Methyl-D-Aspartate Receptor Posttraumatic Stress Disorder
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Rajabi F, Fozveh F, Maracy MR. The Effect of Add-on Memantine in New Onset Combat-Related Posttraumatic Stress Disorder Core Symptoms: A Pilot Study. Iran J Psychiatry. 2023;18(3):266-274.